Ilias A, Szanto K, Gonczi L, et al. - Through a prospective observational study of 174 unselected and consecutive individuals with IBD (136 with Crohn disease [CD] and 38 with ulcerative colitis [UC]) who received maintenance therapy with the biosimilar in Hungary, experts assessed the impact of a reverse switch (from a biosimilar to Remicade) in a real-life cohort. Data from a real-life cohort of individuals with CD or UC who were switched from maintenance therapy with a biosimilar to Remicade or were treated with only Remicade was gathered. In individuals switched from the biosimilar to Remicade, no important variations were noted in remission, trough levels, or antidrug antibodies. No new safety signals were discovered.